Journal Article

Telehealth effectiveness for pre‐exposure prophylaxis delivery in Brazilian public services: the Combine! Study

Kruppa, Mariele, Peres, Maria Fernanda Tourinho, Neves, Lis Aparecida de Souza, de Quadros Winkler, Lisiane, Leal, Andréa Fachel, Neto, José Eluf, Munhoz, Rosemeire, de Moraes, Renata Amaral, Arruda, Érico, Santos, Juliane Cardoso Villela, Koyama, Mitti Ayako Hara, Estevam, Denize Lotufo, Escuder, Maria Mercedes, Grangeiro, Alexandre, Couto, Marcia Thereza, Santos, Lorruan Alves do, Zucchi, Eliana Miura

2023

Overview

Introduction: Pre‐exposure prophylaxis (PrEP) delivery based on user needs can enhance PrEP access and impact. We examined whether telehealth for daily oral PrEP delivery could change the indicators of care related to prophylactic use in five Brazilian public HIV clinics (testing centres, outpatient clinics and infectious disease hospitals). Methods: Between July 2019 and December 2020, clients on PrEP for at least 6 months could transition to telehealth or stay with in‐person follow‐up. Clients were clinically monitored until June 2021. A desktop or mobile application was developed, comprising three asynchronous consultations and one annual in‐person consultation visit. Predictors influencing telehealth preference and care outcomes were examined. The analysis encompassed intent‐to‐treat (first choice) and adjustments for sexual practices, schooling, age, duration of PrEP use and PrEP status during the choice period. Results: Of 470 users, 52% chose telehealth, with the adjusted odds ratio (aOR) increasing over time for PrEP use (aOR for 25–months of use: 4.90; 95% CI: 1.32–18.25), having discontinued PrEP at the time of the choice (aOR: 2.91; 95% CI: 1.40–6.06) and having health insurance (aOR: 1.91; 95% CI: 1.24–2.94) and decreasing for those who reported higher‐risk behaviour (aOR for unprotected anal sex: 0.51; 95% CI: 0.29–0.88). After an average follow‐up period of 1.6 years (95% CI: 1.5–1.7), the risk of discontinuing PrEP (not having the medication for more than 90 days) was 34% lower with telehealth (adjusted hazard ratio: 0.66; 95% CI: 0.45–0.97). When adjusted by mixed linear regression, no differences in adherence (measured by mean medication possession rate) were found between in‐person and telehealth (p = 0.486) or at pre‐ and post‐telehealth follow‐ups (p = 0.245). Sexually transmitted infections increased between the pre‐follow‐up and post‐follow‐up choices and were not associated with in‐person or telehealth (p = 0.528). No HIV infections were observed. Conclusions: Our findings indicate that telehealth for PrEP delivery can enhance service rationalization and reinforce the prevention cascade. This approach reduces prophylaxis interruptions and is mainly preferred by individuals with lower demands for healthcare services.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Acquired immune deficiency syndrome / AIDS / Antiretroviral drugs / Brazil / Cities / Coronaviruses / COVID-19 / Demographics / Disease prevention / Drug use / effectiveness / HIV / HIV infection / Hospitals / Human immunodeficiency virus / Infections / Infectious diseases / Laboratories / Methods / Outpatient care facilities / Population / Prevention / pre‐exposure prophylaxis / Professionals / Public health / Questionnaires / Retention / Sexually transmitted diseases / STD / telehealth / Telemedicine